Shenzhen Shenxin Biotechnology Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Shenzhen Shenxin Biotechnology Co., Ltd. - overview
Established
2019
Location
Shenzhen, -, China
Primary Industry
Biotechnology
About
Established in 2019 and based in Shenzhen, China, Shenzhen Shenxin Biotechnology Co. , Ltd. is a biotechnology company that focuses on research and development of core mRNA delivery technology. The company has completed 3 rounds of funding as of 2022.
The company has set up biotech R&D labs in Shenzhen, Nanjing and Hong Kong. Dr. Linxian Li, the company's founder and CEO, holds a PhD from the University of Heidelberg, Germany, was a postdoctoral fellow at MIT, and is currently an assistant professor at Karolinska School of Medicine. The company has an R&D and CMC team of nearly 200 people and a 4500 square meter R&D lab.
The company is engaged in the development of novel preventive and therapeutic vaccines and drugs based on mRNA technology and LNP delivery technology. The company has four major R&D pipelines include infectious disease vaccines, rare diseases, therapeutic oncology vaccines, and oncology immunotherapy boosters.
Current Investors
Casstar Capital, Lanting Capital, Dynamic Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.innorna.com
Verticals
HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.